Authors

Latest:

Payers Still Denying Coverage Despite Clinical Trial Mandate

A mandate enacted after the 2010 Patient Protection and Affordable Care Act was supposed to improve health coverage for patients enrolled in clinical trials; however, nearly 63% of cancer centers and organizations that responded to a recent survey reported insurance denials of routine care costs associated with patient involvement in clinical trials during 2014.

Kelly L. Stratton, MD

Latest:

Urologists Will Need Training in Immuno-Oncology Adverse Events

As immunotherapy has become increasingly utilized, urologists are more frequently participating in the management of patients who are receiving immunotherapy.

Kelly McCann, MD, PhD, Ronald Reagan UCLA Medical Center

Latest:

Dr McCann on Navigating Work-Life Balance As a Woman in Oncology

Kelly E. McCann, MD, PhD, discusses her experiences with mentorship and work-life balance as a woman in oncology.

Kelly Paulson, MD

Latest:

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Kelvin Alexander Moses, MD, PhD

Latest:

Dr. Moses On Ongoing Trials in mHSPC

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Kemp Kernstine, MD, PhD

Latest:

Dr. Kernstine on Variation in Thoracic Surgery Outcomes

Dr. Kemp Kernstine from University of Texas, Southwestern Medical Center Discusses Variation in Thoracic Surgery Outcomes

Ken Y. Yoneda, MD

Latest:

Dr. Yoneda Discusses Pulmonary Nodules

Dr. Ken Y. Yoneda from UC Davis Cancer Center Discusses Pulmonary Nodules

Kendra Harris, MD, MSc

Latest:

Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.

Kendra Sweet, MD

Latest:

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Kendra Sweet, MD, Moffitt Cancer Center

Kenneth Anderson, MD

Latest:

Dr. Anderson on Addressing Unmet Needs in Myeloma With Descartes-11

Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.

Kenneth B. DeSantes, MD

Latest:

University of Wisconsin Team Develops Novel Strategy for High-Risk Neuroblastoma

Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.

Kenneth C. Anderson, MD

Latest:

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Kenneth C. Anderson, MD, Dana-Farber Cancer Institute

Kenneth E. Fleisher, DDS

Latest:

Dr. Fleisher Discusses Monitoring Patients With ONJ

Dr. Ken Fleisher from New York University Discusses Monitoring Patients With ONJ

Kenneth H. Shain, MD, PhD

Latest:

Dr Shain on the Evolving Role of Bispecific Antibodies in Multiple Myeloma Management

Kenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.

Kenneth H. Yu, MD, Memorial Sloan Kettering Cancer Center

Kenneth J. Bloom, MD

Latest:

Dr. Bloom Explains Situations Requiring HER2 Retesting

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Kenneth Kernen, MD, Michigan Institute of Urology

Kenneth M. Kernen, MD

Latest:

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.